General Information of Drug (ID: DMIYJ2M)

Drug Name
STA2 Drug Info
Synonyms 11alpha-carba-9alpha,11beta-thia-Txa2
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5311453
TTD Drug ID
DMIYJ2M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alprostadil DMWH7NQ Aorta coarctation Approved [3]
Ridogrel DMWH9CN Acute myocardial infarction BA41 Approved [4]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [5]
Ramatroban DMB8UQ3 Perennial allergic rhinitis CA08.03 Phase 2/3 [6]
KP-496 DMCO8UZ Asthma CA23 Phase 2 [7]
FK-070 DMJSD5W Angina pectoris BA40 Phase 2 [8]
TAK-128 DMHPEFS Diabetic neuropathy 8C0Z Phase 2 [9]
Ifetroban sodium DMZP84Y Thrombosis DB61-GB90 Phase 2 [10]
Ifetroban DMEV39E Aspirin-induced asthma CA23.20 Phase 2 [11]
YM-57158 DMS31YW Allergic rhinitis CA08.0 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [2]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [13]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [2]
BUTAPROST DMVYNJZ Discovery agent N.A. Patented [14]
DG041 DMVO9WM Peripheral vascular disease BD4Z Discontinued in Phase 2 [15]
GR-63799X DM13GK8 Asthma CA23 Discontinued in Phase 1 [16]
U46619 DM13FX4 Discovery agent N.A. Investigative [17]
carbacyclin DMMBQYE Discovery agent N.A. Investigative [2]
PGD2 DMYDW6J Discovery agent N.A. Investigative [18]
butaprost (free acid form) DM5MZHP Discovery agent N.A. Investigative [17]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin E2 receptor EP3 (PTGER3) TTPNGDE PE2R3_HUMAN Agonist [2]
Thromboxane A2 receptor (TBXA2R) TT2O84V TA2R_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1939).
2 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
3 Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
4 Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42.
5 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
6 Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7.
7 Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
8 Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
9 ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
10 AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
11 Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115.
12 In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
13 IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
14 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
15 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
16 Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.
17 The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
18 Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.